UY36922A - ASGR INHIBITORS - Google Patents

ASGR INHIBITORS

Info

Publication number
UY36922A
UY36922A UY0001036922A UY36922A UY36922A UY 36922 A UY36922 A UY 36922A UY 0001036922 A UY0001036922 A UY 0001036922A UY 36922 A UY36922 A UY 36922A UY 36922 A UY36922 A UY 36922A
Authority
UY
Uruguay
Prior art keywords
asgr
methods
binding proteins
inhibitors
administering
Prior art date
Application number
UY0001036922A
Other languages
Spanish (es)
Inventor
Paul Nioi
Peter Coward
Christopher Murawsky
Derek E Piper
Fernando Garces
Jun Zhang
Yang Li
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY36922A publication Critical patent/UY36922A/en

Links

Abstract

Se describen proteínas de unión al antígeno que interactúan con ASGR, ASGR-1 y/o ASGR-2, así como métodos para producir y utilizar dichas proteínas de unión al antígeno. Métodos para tratar y prevenir la enfermedad cardiovascular mediante la administración de una cantidad farmacéuticamente eficaz de proteínas de unión al antígeno de ASGR, ASGR-1 y/o ASGR-2. Se describen métodos para tratar y prevenir la enfermedad cardiovascular mediante la administración de una cantidad farmacéuticamente eficaz de composiciones de ARN interferente que reducen la expresión de ASGR, ASGR-1 y/o ASGR-2.Antigen binding proteins that interact with ASGR, ASGR-1 and / or ASGR-2 are described, as well as methods for producing and using said antigen binding proteins. Methods for treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of antigen-binding proteins of ASGR, ASGR-1 and / or ASGR-2. Methods for treating and preventing cardiovascular disease are described by administering a pharmaceutically effective amount of interfering RNA compositions that reduce the expression of ASGR, ASGR-1 and / or ASGR-2.

UY0001036922A 2015-09-29 2016-09-28 ASGR INHIBITORS UY36922A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562234546P 2015-09-29 2015-09-29
US201562259533P 2015-11-24 2015-11-24
US201662319740P 2016-04-07 2016-04-07

Publications (1)

Publication Number Publication Date
UY36922A true UY36922A (en) 2017-03-31

Family

ID=58689632

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036922A UY36922A (en) 2015-09-29 2016-09-28 ASGR INHIBITORS

Country Status (2)

Country Link
TW (1) TW201726726A (en)
UY (1) UY36922A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116948030A (en) * 2022-04-25 2023-10-27 武汉大学 anti-ASGR 1 monoclonal antibody and application thereof

Also Published As

Publication number Publication date
TW201726726A (en) 2017-08-01

Similar Documents

Publication Publication Date Title
EA201890285A1 (en) ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
CO2018000104A2 (en) Antibody molecules that bind to cd22
CL2018000429A1 (en) Kras expression modulators
EA201990293A1 (en) MULTI-SPECIFIC ANTIBODIES AGAINST CD40 AND CD137
EA201891983A1 (en) COMBINED THERAPY WITH ANTIBODIES TO CD73
EA201792414A1 (en) ANTIBODIES AGAINST CD166, ACTIVATED ANTIBODIES AGAINST CD166 AND METHODS OF THEIR APPLICATION
CU24498B1 (en) FACTOR XI ANTIBODIES
CO2018000211A2 (en) Antibody molecules that bind to CD45
MX2022011002A (en) Humanized or chimeric cd3 antibodies.
EA201792413A1 (en) ANTIBODIES AGAINST CD71, ACTIVATED ANTIBODIES AGAINST CD71 AND METHODS OF THEIR APPLICATION
EA201890630A1 (en) ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
BR112017001579A2 (en) anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable cd3 antibodies and methods of use
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
MX2018008934A (en) Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same.
EA201891339A1 (en) AQUEOUS PHARMACEUTICAL PREPARATION THAT CONTAINS ANTIBODY TO PD-L1 AVELUMAB
MX2016012124A (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof.
CO2018000410A2 (en) Antibody molecules that bind to cd79
WO2018151821A8 (en) Antibodies to alpha-synuclein and uses thereof
WO2016044189A8 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
PH12014501122A1 (en) Methods of treatment using an antibody against interferon gamma
EA201690881A1 (en) COMPOUNDS INHIBITORS AUTOTAXIN
MX2018015272A (en) Anti-cd98 antibodies and antibody drug conjugates.
BR112015030356A2 (en) methods of treatment of a taupathy
EA201692204A1 (en) COMPOSITIONS AND METHODS OF MODULATING THE EXPRESSION OF COMPLEX B FACTOR
EA201890747A1 (en) METHODS OF TREATING INFLAMMATORY DISEASES

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221129